Table 5. Clinical characteristics of 500 uveitis-affected eyes with and without epiretinal membrane in presence and absence of retinal surface wrinkling.
| Total(n=500) | WITH epiretinal membrane showing retinal surface wrinkling | WITHOUT epiretinal membrane showing retinal surface wrinkling | P-valuea | WITH epiretinal membrane showing no retinal surface wrinkling | WITHOUT epiretinal membrane showing no retinal surface wrinkling | P-valuea | |
|---|---|---|---|---|---|---|---|
| (n=90) | (n=410) | (n=64) | (n=436) | ||||
| Age at onset (years) | <0.001b | 0.018b | |||||
| Mean±SD (range) | 45±19(1–90) | 54±19 (2–87) | 43±18 (1–90) | 50±18(11–84) | 44±19(1–90) | ||
| 0–15, n (%) | 32 (6%) | 2 (2%) | 30 (7%) | 3 (5%) | 29 (7%) | ||
| 16–24, n (%) | 33 (7%) | 5 (6%) | 28 (7%) | 4 (6%) | 29 (7%) | ||
| 25–44, n (%) | 189 (38%) | 18 (20%) | 171 (42%) | 20 (31%) | 169 (39%) | ||
| 45–64, n (%) | 161 (32%) | 34 (38%) | 127 (31%) | 18 (28%) | 143 (33%) | ||
| ≥65, n (%) | 85 (17%) | 31 (34%) | 54 (13%) | 19 (30%) | 66 (15%) | ||
| Gender | 0.211c | 0.398c | |||||
| Female, n (%) | 278 (56%) | 57 (63%) | 221 (54%) | 31 (48%) | 247 (57%) | ||
| Male, n (%) | 222 (44%) | 33 (37%) | 189 (46%) | 33 (52%) | 189 (43%) | ||
| Onset of uveitis | 0.002c | 0.009c | |||||
| Sudden, n (%) | 319 (64%) | 43 (48%) | 276 (67%) | 30 (47%) | 289 (66%) | ||
| Insidious, n (%) | 181 (36%) | 47 (52%) | 134 (33%) | 34 (53%) | 147 (34%) | ||
| Duration of an attack of uveitis | 0.001c | 0.004c | |||||
| Limitedd, n (%) | 318 (64%) | 41 (46%) | 277 (68%) | 29 (45%) | 289 (66%) | ||
| Persistente, n (%) | 182 (36%) | 49 (54%) | 133 (32%) | 35 (55%) | 147 (34%) | ||
| Course of uveitis | 0.001c | 0.004c | |||||
| Acutef, n (%) | 89 (18%) | 10 (11%) | 79 (19%) | 8 (12%) | 81 (19%) | ||
| Recurrentg, n (%) | 237 (47%) | 32 (36%) | 205 (50%) | 21 (33%) | 216 (49%) | ||
| Chronich, n (%) | 174 (35%) | 48 (53%) | 126 (31%) | 35 (55%) | 139 (32%) | ||
| Type of inflammation | 0.464c | 0.992c | |||||
| Granulomatous, n (%) | 74 (15%) | 10 (11%) | 64 (16%) | 10 (16%) | 64 (15%) | ||
| Nongranulomatous, n (%) | 426 (85%) | 80 (89%) | 346 (84%) | 54 (84%) | 372 (85%) | ||
| Laterality of uveitis | 0.104c | 0.967c | |||||
| Unilateral, n (%) | 220 (44%) | 31 (34%) | 189 (46%) | 29 (45%) | 191 (44%) | ||
| Bilateral, n (%) | 280 (56%) | 59 (66%) | 221 (54%) | 35 (55%) | 245 (56%) | ||
| BSCVA (Snellen) | <0.001b | 0.001b | |||||
| Mean±SD (range) | 0.60±0.35 (0–1.6) | 0.40±0.28 (0–1.0) | 0.64±0.35 (0–1.6) | 0.45±0.31 (0–1.35) | 0.62±0.35 (0–1.6) | ||
| <0.1, n (%) | 39 (8%) | 13 (14%) | 26 (6%) | 5 (8%) | 34 (8%) | ||
| 0.1–0.4, n (%) | 150 (30%) | 42 (47%) | 108 (26%) | 28 (44%) | 122 (28%) | ||
| 0.5–1.0, n (%) | 293 (59%) | 35 (39%) | 258 (63%) | 29 (45%) | 264 (60%) | ||
| >1.0, n (%) | 18 (4%) | — | 18 (4%) | 2 (3%) | 16 (4%) | ||
| Etiology of uveitis | 0.001c | 0.731c | |||||
| Infectious uveitis, n (%) | 74 (15%) | 17 (19%) | 57 (14%) | 10 (16%) | 64 (15%) | ||
| Specific clinical entity, n (%) | 124 (25%) | 7 (8%) | 117 (29%) | 15 (23%) | 109 (25%) | ||
| Uveitis associated with systemic disease, n (%) | 82 (16%) | 20 (22%) | 62 (15%) | 14 (22%) | 68 (16%) | ||
| Idiopathic uveitis, n (%) | 229 (44%) | 46 (51%) | 174 (42%) | 25 (39%) | 195 (45%) |
Abbreviation: BSCVA, best spectacle-corrected visual acuity (Snellen).
a
Corrected for multiple testing (Benjamini–Hochberg).
b
Mann–Whitney U-test.
c
χ2-test.
d
≤3 months duration.
e
>3 months duration.
f
Episode characterized by sudden onset and limited duration.
g
Repeated episodes separated by periods of inactivity without treatment ≥3 months in duration.
h
Persistent uveitis with relapse in <3 months after discontinuing treatment.